Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 3Phase 1/2 2

Status

Recruiting 12Completed 6Unknown 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Endocrine 2NET 1

Conditions

Carcinoma, Non-Small-Cell Lung 76Breast Neoplasms 46Colorectal Neoplasms 42Neoplasms 41Neoplasm Metastasis 34Melanoma 31Multiple Myeloma 30Prostatic Neoplasms 29Recurrence 28Stomach Neoplasms 27Pancreatic Neoplasms 27Squamous Cell Carcinoma of Head and Neck 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Lung Neoplasms 25Carcinoma, Renal Cell 25Ovarian Neoplasms 23Lymphoma, Large B-Cell, Diffuse 22Leukemia, Myeloid, Acute 22Triple Negative Breast Neoplasms 21Lymphoma, Non-Hodgkin 21Lymphoma, Follicular 21Leukemia, Lymphocytic, Chronic, B-Cell 19Glioblastoma 19Uterine Cervical Neoplasms 16Myelodysplastic Syndromes 16Lymphoma 16Colonic Neoplasms 15Carcinoma, Transitional Cell 15Lymphoma, Mantle-Cell 14Leukemia 14

Interventions

pembrolizumab 1atezolizumab 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × Carcinoma, Neuroendocrine × Clear all
NCT04471727 2026-02-24

MK-6070-001

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2 Active not recruiting
232 enrolled
EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT03647163 2025-09-16

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Vyriad, Inc.

Phase 1/2 Active not recruiting
33 enrolled
EndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡